Stock Markets12 minutes ago (Jan 15, 2022 05:45AM ET)
LONDON (Reuters) – Consumer goods giant Unilever (NYSE:UL) has made a bid for pharmaceutical group Glaxosmithkline (LON:GSK)’s consumer goods business worth roughly 50 billion pounds ($68.4 billion), Britain’s Sunday Times reported.
GSK and Pfizer (NYSE:PFE), which owns a minority stake in the division, were understood to have rejected the offer on the basis that it was too low, the newspaper said.
($1 = 0.7314 pounds)
Unilever offers 50 billion pounds for GSK unit -report
AMSTERDAM (Reuters) – Apple (NASDAQ:AAPL) said on Saturday it would allow developers of dating apps in the Netherlands to offer non-Apple payment options to their users, complying…
By Aditi Shah NEW DELHI (Reuters) – India, which has among the world’s deadliest roads, on Saturday proposed mandating at least six air bags in all passenger cars manufactured…
By Diane Bartz and Elizabeth Culliford WASHINGTON (Reuters) – Multiple states have begun investigating potential violations in how Facebook (NASDAQ:FB), now known as Meta…
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
(C) 2007-2022 Fusion Media Limited. All Rights Reserved
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.